Skin Cancer Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Skin cancer is the most common cancer worldwide, with over 5 million cases diagnosed annually in the United States alone. Skin cancers are broadly classified into non-melanoma skin cancers (NMSC) — basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) — and melanoma, which is far less common but responsible for the vast majority of skin cancer mortality due to its high metastatic potential. Merkel cell carcinoma, dermatofibrosarcoma protuberans, and cutaneous lymphomas represent rarer skin malignancies requiring specialist oncology management.

BCC arises from basal cells of the epidermis, is locally destructive but rarely metastasises, and accounts for approximately 80% of NMSC. UV radiation is the dominant risk factor. BCC presents as pearly, translucent papules or nodules with telangiectasia on sun-exposed skin (face, scalp, ears), ulcerated lesions, or morphoeic (scar-like) plaques. SCC arises from keratinocytes and carries a higher risk of regional lymph node metastasis (approximately 2–5% overall, higher for high-risk features including size greater than 2 cm, poor differentiation, perineural invasion, immunosuppressed patient). Actinic keratoses — UV-induced intraepidermal keratinocyte dysplasia — are the precursor lesions to cutaneous SCC and are treated to prevent progression.

Melanoma arises from melanocytes and is staged by the AJCC 8th Edition system based on tumour thickness (Breslow depth), ulceration, mitotic rate, sentinel lymph node status, and presence of distant metastases. Early-stage melanoma (Stage I–II, localised) is curable with wide local excision alone, with 5-year survival exceeding 90–95% for thin tumours. Advanced melanoma (Stage III–IV) has been revolutionised by immune checkpoint inhibitors (anti-PD-1: pembrolizumab, nivolumab; anti-CTLA-4: ipilimumab) and BRAF/MEK targeted therapy (for BRAF V600E-mutant melanoma), converting a disease with median survival of 6–9 months in the pre-immunotherapy era to 5-year survival rates of 40–50% in Stage IV.

Basal cell carcinoma treatment is guided by tumour subtype, location, size, and patient factors. Low-risk BCC (small, primary, well-defined, non-aggressive histology, not on high-risk sites) is treated with standard surgical excision with 3–4 mm margins or curettage and electrodesiccation. Mohs micrographic surgery — staged excision with immediate intraoperative histological mapping of all margins — is indicated for high-risk BCC: recurrent, poorly defined borders, aggressive histological subtype, facial high-risk areas (nose, ears, periorbital, perioral), and large lesions. Mohs surgery achieves 5-year cure rates of 99% for primary BCC and 94–96% for recurrent lesions — higher than any other treatment modality. Advanced or metastatic BCC unresectable by surgery or radiotherapy is treated with hedgehog pathway inhibitors vismodegib or sonidegib.

Squamous cell carcinoma of the skin is excised with 4–6 mm margins for low-risk lesions, wider margins for high-risk lesions, and Mohs surgery for high-risk site SCC on face/ears/scalp. High-risk SCC features (diameter greater than 2 cm, depth greater than 4 mm, poor differentiation, perineural invasion, immunosuppressed host) require multidisciplinary tumour board review and may warrant sentinel lymph node biopsy or elective nodal dissection. Advanced cutaneous SCC not amenable to surgery or radiation is now treated with cemiplimab (anti-PD-1), the first immunotherapy approved for cutaneous SCC, with objective response rates of approximately 50%.

Melanoma treatment is stage-dependent. Stage I–II localised melanoma is treated with wide local excision with margins determined by Breslow depth (0.5 cm for in-situ, 1 cm for Breslow 0.1–2.0 mm, 2 cm for Breslow greater than 2 mm) and sentinel lymph node biopsy for tumours greater than 0.8 mm or with adverse features. Stage III (regional nodal or in-transit metastases) melanoma is treated with complete lymph node dissection or surveillance plus adjuvant immunotherapy (pembrolizumab) or targeted therapy (dabrafenib/trametinib for BRAF-mutant). Stage IV melanoma is treated with first-line combination immunotherapy (nivolumab plus ipilimumab) or BRAF/MEK inhibitors for BRAF-mutant disease.

All confirmed diagnoses of skin cancer require treatment — untreated BCC causes progressive local tissue destruction, and untreated SCC and melanoma carry metastatic risk. Surgical treatment is appropriate for the vast majority of skin cancers. Mohs surgery is specifically indicated for BCCs and SCCs on high-risk facial sites where tissue conservation is important (nose, eyelid, ear, lip, scalp) or where standard margin excision would sacrifice unacceptably large amounts of tissue. Patients with immunosuppression (organ transplant recipients, HIV, chronic immunosuppressive therapy) are at markedly elevated risk of aggressive SCC and require vigilant surveillance and low threshold for biopsy and aggressive treatment.

For immunotherapy of advanced melanoma, patient eligibility assessment includes performance status (ECOG 0–2), autoimmune history (relative contraindication for checkpoint inhibitors), organ function (hepatic, renal, pulmonary), and BRAF mutation status (determines BRAF/MEK targeted therapy eligibility). Patients with active autoimmune conditions requiring systemic immunosuppression require careful benefit-risk assessment before checkpoint inhibitor therapy. Elderly or frail patients with multiple comorbidities and low-risk BCC may be candidates for non-surgical treatments (topical imiquimod for superficial BCC, radiotherapy) if surgery carries disproportionate risk.

Mohs micrographic surgery (MMS) is the gold standard for high-risk BCC and SCC on critical anatomical sites. Performed under local anaesthesia as an outpatient procedure, each stage involves tissue excision, horizontal sectioning, and real-time cryostat histological examination of 100% of the peripheral and deep margins — unlike standard permanent section margin assessment which samples only a small percentage of the margin. Stages are repeated until clear margins are confirmed, minimising unnecessary tissue removal while ensuring complete tumour excision.

Standard surgical excision is appropriate for well-defined, low-risk NMSC — performed with predetermined clinical margins, sent to pathology for standard processing, with results in 5–7 days. Wide local excision for melanoma requires margin sizes determined by NCCN/ESMO guidelines based on Breslow depth. Curettage and electrodesiccation (C&E) is suitable for small, primary, superficial BCC only. Non-surgical options for superficial BCC include topical imiquimod (Aldara, 5 days per week for 6 weeks) with approximately 80% histological clearance rate, and topical 5-fluorouracil (5-FU, twice daily for 6 weeks). Photodynamic therapy (PDT) using topical aminolevulinic acid (ALA) or methyl aminolevulinate (MAL) sensitiser with red light (630 nm) activation treats superficial BCC and actinic keratoses with 80–90% clearance for AKs and 75–85% for sBCC.

For advanced melanoma, nivolumab plus ipilimumab (CheckMate 067) achieves objective response rates of 58% and median overall survival exceeding 60 months in Stage IV melanoma. BRAF-mutant Stage IV melanoma treated with dabrafenib plus trametinib achieves 60–70% objective response rates with rapid clinical benefit. Anti-PD-1 monotherapy (pembrolizumab, nivolumab) achieves 40–45% objective response rates with durable remissions. Radiotherapy is used as adjuvant treatment for resected high-risk cutaneous SCC, for inoperable tumours, and in brain metastasis management in melanoma.

Mohs surgery achieves 5-year cure rates of 98–99% for primary BCC and 94–96% for recurrent BCC — significantly superior to standard excision (95% primary, 83% recurrent) and radiation therapy. The tissue-sparing nature of Mohs surgery is particularly valuable on the nose, eyelid, ear, and lip, minimising reconstruction complexity. The cosmetic outcome of Mohs-guided reconstruction by experienced Mohs surgeons rivals or exceeds standard excision.

Early-stage melanoma outcomes are excellent — Stage IA (Breslow less than 0.8 mm, no ulceration) has 5-year survival exceeding 98% with wide local excision alone. The immunotherapy revolution has transformed Stage IV melanoma outcomes: the CheckMate 067 trial demonstrated 5-year overall survival of 52% for nivolumab plus ipilimumab combination — compared to historical 5-year survival of less than 5% for Stage IV melanoma in the dacarbazine era. For BRAF V600E/K mutant Stage IV melanoma, BRAF/MEK combination (dabrafenib/trametinib) achieves 3-year overall survival of 45% in COMBI-d/v trials. Adjuvant pembrolizumab for resected Stage III melanoma reduces recurrence risk by approximately 35% compared to placebo in KEYNOTE-054, converting some patients who would have relapsed to long-term disease-free survival.

Surgical excision of skin cancer carries standard surgical risks — bleeding, infection, wound dehiscence, and scarring. On the face, particularly the nose, lip, and eyelid, functional outcomes (eye closure, nasal airway, oral competence) and aesthetic outcomes depend heavily on the reconstruction technique and surgeon experience. Post-Mohs reconstruction options include primary closure, local flaps (nasolabial, paramedian forehead), or skin grafts — each with specific aesthetic and functional considerations.

Topical treatments for superficial BCC (imiquimod, 5-FU) cause expected local inflammatory reactions — erythema, crusting, ulceration — that can be intense and occasionally painful; patients must be counselled that these reactions indicate treatment activity and do not indicate complications. Checkpoint inhibitor immunotherapy for advanced melanoma causes immune-related adverse events (irAEs) mediated by activated T-cells attacking normal tissues: immune-mediated dermatitis (rash, vitiligo), colitis, hepatitis, endocrinopathies (thyroiditis, hypophysitis, adrenal insufficiency, type 1 diabetes), pneumonitis, and rare neurological or cardiac toxicities. Grade 3–4 irAEs occur in 15–30% of patients on nivolumab/ipilimumab combination. BRAF/MEK inhibitors cause pyrexia, arthralgias, skin rash, and secondary cutaneous SCC (paradoxical MAPK pathway activation in BRAF wild-type cells). Radiotherapy complications include radiation dermatitis, mucositis for head and neck sites, and late-onset fibrosis.

After surgical treatment of BCC or SCC, wound check at 5–7 days for suture care, and dermatological follow-up at 3 months for surgical site review. Dermatological surveillance every 6–12 months for life is recommended for all patients who have had skin cancer — the risk of subsequent BCC, SCC, or melanoma is significantly elevated. Full skin examination at each visit with dermoscopy of suspicious lesions. Patients are instructed in self-skin examination technique and sun protection behaviour.

For melanoma, follow-up schedule is risk-stratified: Stage I–II patients are seen every 3–6 months for 2 years, then annually; Stage III–IV patients are followed every 3 months for the first 2 years with CT imaging at 3–6 monthly intervals to detect relapse early for clinical trial eligibility. Immunotherapy for advanced melanoma is delivered by oncology infusion centres — 3-weekly or 6-weekly intervals — with toxicity monitoring (blood counts, liver function, thyroid function, cortisol at baseline) before each cycle. Patients on checkpoint inhibitors must be educated on the specific symptoms of irAEs (persistent diarrhoea, colitis symptoms, dyspnoea, rash, endocrine symptoms) requiring urgent oncology contact.

Skin cancer treatment costs vary dramatically by type and stage. In the United States, Mohs micrographic surgery with reconstruction costs USD 2,000–6,000 depending on complexity and reconstruction required. Standard excision under local anaesthesia in a dermatologist's office costs USD 500–1,500. Sentinel lymph node biopsy for melanoma adds USD 3,000–8,000. Adjuvant pembrolizumab for Stage III melanoma costs USD 15,000–25,000 per month in the US before insurance. First-line nivolumab plus ipilimumab for Stage IV melanoma costs USD 40,000–60,000 per treatment course.

For patients requiring skin cancer surgery who lack insurance coverage, India and Thailand offer Mohs surgery equivalent procedures at major cancer centres for USD 300–1,500, with well-equipped dermatosurgery units at Tata Memorial Centre, AIIMS, and Bumrungrad International. For advanced melanoma requiring immunotherapy, biosimilar and generic access varies globally — in India, pembrolizumab biosimilars are available at approximately USD 500–1,500 per dose compared to USD 10,000+ in the US. Patients travelling internationally for advanced melanoma treatment should ensure continuity of irAE monitoring protocols with a local oncologist.

Radiotherapy is an effective alternative to surgery for primary BCC and SCC in patients who are not surgical candidates — elderly patients, extensive morphoeic BCC, or tumours where surgery would produce unacceptable functional deficit. 5-year local control rates for radiotherapy for BCC are 90–95% but lower than Mohs surgery for high-risk lesions. Superficial radiotherapy (SRT), contact brachytherapy (Papillon technique), and electron beam radiotherapy are deployed according to tumour depth and location. Electrochemotherapy combining bleomycin intralesional injection with electropermeabilisation pulses is used for cutaneous metastases from melanoma and SCC as a palliative local tumour control modality.

Clinical trial participation is a critical option — particularly for advanced melanoma where emerging combinations (LAG-3 inhibitors, TIGIT inhibitors, personalised mRNA vaccines, TIL adoptive cell therapy) are being tested in phase 2–3 trials at academic oncology centres. For actinic keratoses (precancers), photodynamic therapy (PDT), topical ingenol mebutate, diclofenac 3% gel, and field-directed cryotherapy with fluorouracil treat the field of sun-damaged skin containing multiple subclinical AKs, reducing the burden of SCC precursor lesions more effectively than treating individual AKs one by one.